title: [Therapy of carcinomatous peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration].
abstract: In order to perform therapy for carcinomatous peritonitis by a new angiogenesis inhibitor, TNP-470, we investigated the effective timing and the optimal doses for intraperitoneal administration using two mice models. In both carcinomatous peritonitis models caused by M 5076 tumor and B 16 melanoma, the early administration of TNP-470 within one week after tumor inoculation extended the survival times of the mice receiving the drugs, whereas the administration of TNP-470 one week or later after inoculation did not affect the survival time. However, there were significant differences in the effective therapeutic doses of TNP-470 between the two models. It is important to select the best timing and doses for intraperitoneal administration of TNP-470 based on the state of angiogenesis and the sensitivity of the tumor tissues to TNP-470.
authors.affiliation: First Dept. of Surgery, Kyoto Prefectural University of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Tsujimoto
authors.forename: K
authors.initials: K
authors.lastname: Osaki
authors.forename: T
authors.initials: T
authors.lastname: Ohyama
authors.forename: T
authors.initials: T
authors.lastname: Sakakibara
authors.forename: M
authors.initials: M
authors.lastname: Ohgaki
authors.forename: T
authors.initials: T
authors.lastname: Imanishi
authors.forename: J
authors.initials: J
authors.lastname: Yamasaki
authors.forename: M
authors.initials: M
authors.lastname: Shirasu
authors.forename: M
authors.initials: M
authors.lastname: Shimotsuma
authors.forename: A
authors.initials: A
authors.lastname: Hagiwara
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003510:Cyclohexanes; D007263:Infusions, Parenteral; D008297:Male; D008546:Melanoma, Experimental / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009361:Neoplasm Invasiveness; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010538:Peritonitis / Q000188:drug therapy* / Q000473:pathology; D012513:Sarcoma, Experimental / Q000473:pathology*; D012717:Sesquiterpenes / Q000008:administration & dosage*
chemical_list: D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol